Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are administered as standard first-line regimen for advanced EGFR-mutant non-small cell lung cancer (NSCLC) [3–5], the salvage treatment for cases with acquired resistance to EGFR-TKIs remains unclear. Here, EGFR is linked to non-small cell lung carcinoma.